Fatima Yousif Alshamsi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatima Yousif Alshamsi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Aisha Hanaya Alsuwaidi
Centre for Biotechnology, Biomedical Engineering Department, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
1 shared publicationAisha Shigna Nadukkandy
Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven and Center for Cancer Biology, VIB, Leuven, Belgium
1 shared publication- Balqees Almazrouei
Centre for Biotechnology, Biomedical Engineering Department, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
1 shared publication - Firda Rahmadani
Department of Management Science & Engineering, Khalifa University of Science & Technology, Abu Dhabi, UAE
1 shared publication - Habiba Alsafar
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, UAE
1 shared publication - Halima Alnaqbi
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, UAE
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 18, 3051-3062
Streamlining Patient Fall Prevention and Management Through Human-Centered AI-Based Decision Support Systems
Patient falls are a major concern in healthcare due to their impact on patient safety, prolonged hospital stays, and increased costs. Traditional fall prevention methods often lack precision and adaptability, emphasizing the need for predictive approaches. This study reviews the current literature and explores the integration of human-centered artificial intelligence (AI)-based decision support systems to improve fall prevention through proactive risk assessment and prediction. This system enables early identification of fall risks, facilitating personalized interventions and real-time monitoring via advanced sensors and wearable devices. These technologies may provide timely alerts to caregivers and support administrators in optimizing resource allocation. Additionally, this study highlights the importance of systems thinking, recognizing patient falls as outcomes of interconnected system failures. By leveraging causal loop analysis and feedback mechanisms, healthcare stakeholders can develop dynamic, system-wide strategies to enhance fall prevention and operational efficiency.
- 1 September 2025
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 18, 3051-3062
Open AccessStreamlining Patient Fall Prevention and Management Through Human-Centered AI-Based Decision Support Systems
Patient falls are a major concern in healthcare due to their impact on patient safety, prolonged hospital stays, and increased costs. Traditional fall prevention methods often lack precision and adaptability, emphasizing the need for predictive approaches. This study reviews the current literature and explores the integration of human-centered artificial intelligence (AI)-based decision support systems to improve fall prevention through proactive risk assessment and prediction. This system enables early identification of fall risks, facilitating personalized interventions and real-time monitoring via advanced sensors and wearable devices. These technologies may provide timely alerts to caregivers and support administrators in optimizing resource allocation. Additionally, this study highlights the importance of systems thinking, recognizing patient falls as outcomes of interconnected system failures. By leveraging causal loop analysis and feedback mechanisms, healthcare stakeholders can develop dynamic, system-wide strategies to enhance fall prevention and operational efficiency.
- Top Cited Papers
- 22 June 2023
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 23 (8) , 544-564
Understanding tumour endothelial cell heterogeneity and function from single-cell omics
Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics studies of tumour endothelial cells (TECs) have provided new mechanistic insight. Here, we overview the heterogeneity of human TECs of all tumour types studied to date, at the single-cell level. Notably, most human tumour types contain varying numbers but only a small population of angiogenic TECs, the presumed targets of AATs, possibly contributing to the limited efficacy of and resistance to AATs. In general, TECs are heterogeneous within and across all tumour types, but comparing TEC phenotypes across tumours is currently challenging, owing to the lack of a uniform nomenclature for endothelial cells and consistent single-cell analysis protocols, urgently raising the need for a more consistent approach. Nonetheless, across most tumour types, universal TEC markers (ACKR1, PLVAP and IGFBP3) can be identified. Besides angiogenesis, biological processes such as immunomodulation and extracellular matrix organization are among the most commonly predicted enriched signatures of TECs across different tumour types. Although angiogenesis and extracellular matrix targets have been considered for AAT (without the hoped success), the immunomodulatory properties of TECs have not been fully considered as a novel anticancer therapeutic approach. Therefore, we also discuss progress, limitations, solutions and novel targets for AAT development.
- 22 June 2023
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 23 (8) , 544-564
Top Cited PapersUnderstanding tumour endothelial cell heterogeneity and function from single-cell omics
Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics studies of tumour endothelial cells (TECs) have provided new mechanistic insight. Here, we overview the heterogeneity of human TECs of all tumour types studied to date, at the single-cell level. Notably, most human tumour types contain varying numbers but only a small population of angiogenic TECs, the presumed targets of AATs, possibly contributing to the limited efficacy of and resistance to AATs. In general, TECs are heterogeneous within and across all tumour types, but comparing TEC phenotypes across tumours is currently challenging, owing to the lack of a uniform nomenclature for endothelial cells and consistent single-cell analysis protocols, urgently raising the need for a more consistent approach. Nonetheless, across most tumour types, universal TEC markers (ACKR1, PLVAP and IGFBP3) can be identified. Besides angiogenesis, biological processes such as immunomodulation and extracellular matrix organization are among the most commonly predicted enriched signatures of TECs across different tumour types. Although angiogenesis and extracellular matrix targets have been considered for AAT (without the hoped success), the immunomodulatory properties of TECs have not been fully considered as a novel anticancer therapeutic approach. Therefore, we also discuss progress, limitations, solutions and novel targets for AAT development.